T-cell vaccination in therapy of multiple sclerosis

Abstract

Multiple sclerosis (MS) is a autoimmune disease, due to developing inflammatory focuses of demyelination in the Central Nervous System. T-cell vaccination is a treatment method aimed at stimulating the antiidiotype, immune reactions that are capable of inactivating idiotype, self-reactive lymphocytes. The experimental and clinical data presented in this review indicate that the mechanism of influencing the T-cell vaccination on the MS-causing, autoimmune process includes 4 components: 1) generation of antiidiotypic, CD8⁺, cytotoxic T-lymphocytes; 2) generation of antiidiotypic CD4⁺ T-helper cells of 2 and 3 type; 3) stimulation of functionality of CD4⁺, CD25⁺ regulatory T cells; and 4) induction of synthesizing antiidiotypic antibodies. The published data suggest expediency of applying T-cell vaccination in the treatment for MS and other autoimmune diseases.

Keywords

multiple sclerosis / T-cell vaccinaton / T-cell receptor

References

[1] Giuliani F., Yong V.W. Immune-mediated neurodegeneration and neuroprotection in MS. Int. MS J. 2003; 10: 122—30.

[2] Stbve O., Cravens P.D., EagarT.N. DNA-based vaccines: the future of multiple sclerosis therapy? Expert Rev. Neurother. 2008; 8: 351—60.

[3] Zhang J. T cell vaccination as an immunotherapy for autoimmune diseases. Cell. Mol. Immunol. 2004; 1: 321—7.

[4] Tejada-Simon M.V., Zang Y.C., Yang D. Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int. Immunol. 2000; 12: 1641-50.

[5] Hafler D. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J. Clin. Invest. 1999; 104: 527—9.

[6] Soldan S.S., Berti R., Salem N. Association of human herpes virus 6 CHHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat. Med. 1997; 3: 394—7.

[7] Prinz M., Garbe F., Schmidt H. et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 2006; 116: 456-64.

[8] Tsunoda I., Tolley N.D., Theil D.J. et al. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol. 1999; 9: 481-93.

[9] Clark D. Human herpesvirus type 6 and multiple sclerosis. Herpes. 2004;11 Suppl 2: 112A-9A.

[10] Lbnemann J.D., KamradtT., Martin R , Mbnz C. Epstein-barr virus: environmental trigger of multiple sclerosis? J. Virol. 2007; 81: 6777—84.

[11] Kebir H., Kreymborg K., Ifergan I. et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007; 13: 1173-5.

[12] Giuliani F., Goodyer C.G., Antel J.P., Yong V.W. Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol. 2003; 171: 368-79.

[13] Huan J., Culbertson N.. Spencer L. et al. Decreased F0XP3 levels in multiple sclerosis patients. J. Neurosci. Res. 2005; 81: 45—52.

[14] Astier A.L., Meiffren G., Freeman S., Hafler D.A. Alterations in CD46-mediated Trl regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 2006:116: 3252-57.

[15] Vandenbark A.A., Finn T., Barnes D. Diminished frequency of IL-10 secreting, TCR peptide-reactive T-cells in multiple sclerosis patients may allow expansion of activated memory T-cells bearing the cognate BV gene. J. Neurosci. Res. 2001; 66: 171—6.

[16] Antel J., Bania M., Noronha A., Neely S. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. J. Immunol. 1986; 137: 3436—9.

[17] Correale J., Farez M., Gilmore W. Vaccines for multiple sclerosis: progress to date. CNS Drugs. 2008; 22: 175—98.

[18] Cohen I.R. Natural Id-anti-ld networks and the immunological homunculus. In: Atlan H., Cohen I.R., editors. Theories of Immune Networks. Berlin: Springer-Verlag; 1986: 6—12.

[19] Hafler D., Cohen I.R.O, Benjamine D., Weiner H.L. T cell vaccination in multiple sclerosis: a preliminary report. Clin. Immunol. Immunopath. 1998; 62: 307-12.

[20] Zhang J., Medaer R., Stinissen P., Hafler D.A., Raus J. MHC restricted clonotypic depletion of human myelin basic protein-reactive T- cells by T cell vaccination. Science 1993; 261: 1451—4.

[21] Zhang J., Raus J. T cell vaccination trial in multiple sclerosis, in T- cell vaccination and autoimmune disease. In: Zhang J., Raus J., editors. Autoimmune disease and T cell vaccination. Austin: Springer-Verlag, Landes Medical Publishers, 1995. p. 135—60.

[22] Correale J., Lund B., McMillan M. et al. T cell vaccination in secondary progressive multiple sclerosis. J. Neuroimmunol. 2000; 107: 130-9.

[23] Zhang J.Z., Rivera V.M., Tejada-Simon M.V. et al. T-cell vaccination in multiple sclerosis: results of a preliminary study. J. Neurol. 2002; 249: 212-8.

[24] Achiron A., Lavie G., Kishner I. et al. T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin. Immunol. 2004; 113: 155-60.

[25] Иванова И.П., Селедцов В.И., Банул Н.В. и др. Получение Т-клеточной вакцины и ее применение для лечения рассеянного склероза. Медицинская иммунология 2005; 7: 27—32.

[26] Иванова И.П., Селедцов В.И., Селедцов Д.В. и др. Индукция антиидиотипического иммунного ответа поликлональной Т-клеточной вакциной у больных рассеянным склерозом. Клеточные технологии в биологии и медицине 2008 [в печати.).

[27] Morgan Е.Е., Nardo C.J., Diveley J.P. et al. Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis. J. Neurosci. Res. 2001; 64: 298—301.

[28] Bourdette D.N., Edmonds E., Smith C. et al. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult. Scler. 2005; 11: 552-61.

[29] Vandenbark A.A., Culbertson N.E., Bartholomew R.M. et al. Therapeutic vaccination with a trivalent T-cell receptor tTCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunol.2008; 123: 66—78.

[30] Zang Y., Hong J., Rivera V. et al. Preferential recognition of hypervariable region sequence by antiidiotypic T cells induced by T-cell vaccination in patients with multiple sclerosis. J. Immunol. 2000; 164: 4011-7.

[31] 31 .Vandenbark A.A. TCR peptide vaccination in multiple sclerosis: Boosting a deficient regulatory network that may involve TCRspecific CD4+CD25+ Treg cells. Curr. Drug Targets Inflamm. Allergy 2005; 4: 85-94.

[32] Hong J., Zang Y.C., Nie H., Zhang J.Z. CD4+ regulatory T-cell responses induced by T cell vaccination in patients with multiple sclerosis. PNAS USA 2006; 103: 5024-9.

[33] Stinissen P., Zhang J., Vandevyver C. et al. T cell responses to activated T cells in multiple sclerosis patients induced by T cell vaccination. J. Neuroimmunol. 1998; 87: 94—104.

[34] Zang Y., Hong J., Tejada-Simon M. Th2 immune regulation induced by T-cell vaccination in patients with multiple sclerosis. Eur. J. Immunol. 2000; 30: 908-13.

[35] Hong J., Zang Y., Rivera V., Zhang J. Reactivity and regulatory properties of anti-idiotypic antibodies induced by T-cell vaccination in patients with multiple sclerosis. J. Immunol. 2000; 165: 6858—64.

[36] Ito K., Tanaka T., Tsutsumi N., Obata F., Kashiwag N. Possible mechanisms of immunotherapy for maintaining pregnancy in recurrent spontaneous aborters: analysis of anti-idiotypic antibodies directed against autologous T-cell receptor. Hum. Reprod. 1999; 14: 650—5.

RIGHTS & PERMISSIONS

Eco-Vector